MXPA03003485A - Moduladores del receptor de estrogenos. - Google Patents

Moduladores del receptor de estrogenos.

Info

Publication number
MXPA03003485A
MXPA03003485A MXPA03003485A MXPA03003485A MXPA03003485A MX PA03003485 A MXPA03003485 A MX PA03003485A MX PA03003485 A MXPA03003485 A MX PA03003485A MX PA03003485 A MXPA03003485 A MX PA03003485A MX PA03003485 A MXPA03003485 A MX PA03003485A
Authority
MX
Mexico
Prior art keywords
group
alkyl
ppm
halogen
nmr
Prior art date
Application number
MXPA03003485A
Other languages
English (en)
Spanish (es)
Inventor
Frank P Dininno
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of MXPA03003485A publication Critical patent/MXPA03003485A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D411/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D411/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D327/00Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/06Six-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D339/00Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/08Six-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MXPA03003485A 2000-10-19 2001-10-15 Moduladores del receptor de estrogenos. MXPA03003485A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24158200P 2000-10-19 2000-10-19
PCT/US2001/042735 WO2002032377A2 (en) 2000-10-19 2001-10-15 Estrogen receptor modulators

Publications (1)

Publication Number Publication Date
MXPA03003485A true MXPA03003485A (es) 2003-07-14

Family

ID=22911282

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03003485A MXPA03003485A (es) 2000-10-19 2001-10-15 Moduladores del receptor de estrogenos.

Country Status (20)

Country Link
EP (1) EP1333827A2 (xx)
JP (1) JP2004511502A (xx)
KR (1) KR20030042020A (xx)
CN (1) CN1469743A (xx)
AU (2) AU2002232381B2 (xx)
BG (1) BG107676A (xx)
BR (1) BR0114689A (xx)
CA (1) CA2424729A1 (xx)
EA (1) EA200300474A1 (xx)
EC (1) ECSP034558A (xx)
EE (1) EE200300153A (xx)
HU (1) HUP0303563A2 (xx)
IL (1) IL154984A0 (xx)
IS (1) IS6761A (xx)
MX (1) MXPA03003485A (xx)
NO (1) NO20031737L (xx)
PE (1) PE20021083A1 (xx)
PL (1) PL361053A1 (xx)
SK (1) SK4772003A3 (xx)
WO (1) WO2002032377A2 (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225132A1 (en) * 2002-04-11 2003-12-04 Dininno Frank P. Estrogen receptor modulators
WO2003091239A1 (en) 2002-04-24 2003-11-06 Merck & Co., Inc. Estrogen receptor modulators
JP4500689B2 (ja) * 2002-12-26 2010-07-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 選択的エストロゲン受容体モジュレーター
KR101431279B1 (ko) * 2005-07-29 2014-08-20 리스버로직스 코퍼레이션 복합 질환의 예방 및 치료용 약학적 조성물 및 삽입가능한의료 장치에 의한 이의 전달
JPWO2007049798A1 (ja) * 2005-10-27 2009-04-30 萬有製薬株式会社 新規ベンゾオキサチイン誘導体
PL2118074T3 (pl) 2007-02-01 2014-06-30 Resverlogix Corp Związki chemiczne do celów profilaktyki i leczenia chorób układu sercowo-naczyniowego
ES2463097T3 (es) 2009-01-08 2014-05-27 Resverlogix Corp. Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares
US9238640B2 (en) 2009-03-18 2016-01-19 Resverlogix Corp. Anti-inflammatory agents
NZ596117A (en) 2009-04-22 2014-10-31 Resverlogix Corp Novel anti-inflammatory agents
EP3205648A1 (en) 2010-06-10 2017-08-16 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
WO2011159769A2 (en) 2010-06-17 2011-12-22 Aragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
HUE044986T2 (hu) 2011-11-01 2019-11-28 Resverlogix Corp Orális, azonnali felszabadulású készítmények szubsztituált kinazolinonokhoz
EA029559B1 (ru) 2011-12-14 2018-04-30 Серагон Фармасьютикалс, Инк. Фторированные модуляторы рецепторов эстрогенов и их применение
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
KR20150096794A (ko) 2012-12-21 2015-08-25 제니쓰 에피제네틱스 코포레이션 브로모도메인 저해제로서의 신규한 헤테로사이클릭 화합물
CN114984016A (zh) 2015-03-13 2022-09-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法

Also Published As

Publication number Publication date
NO20031737D0 (no) 2003-04-15
IL154984A0 (en) 2003-10-31
WO2002032377A3 (en) 2002-08-22
KR20030042020A (ko) 2003-05-27
SK4772003A3 (en) 2003-08-05
PE20021083A1 (es) 2002-12-16
EE200300153A (et) 2003-06-16
PL361053A1 (en) 2004-09-20
HUP0303563A2 (hu) 2004-03-01
AU2002232381B2 (en) 2004-11-18
IS6761A (is) 2003-03-27
ECSP034558A (es) 2003-06-25
BG107676A (bg) 2003-11-28
EA200300474A1 (ru) 2003-10-30
AU3238102A (en) 2002-04-29
NO20031737L (no) 2003-06-19
BR0114689A (pt) 2003-07-01
WO2002032377A2 (en) 2002-04-25
EP1333827A2 (en) 2003-08-13
JP2004511502A (ja) 2004-04-15
CN1469743A (zh) 2004-01-21
CA2424729A1 (en) 2002-04-25

Similar Documents

Publication Publication Date Title
MXPA03003485A (es) Moduladores del receptor de estrogenos.
AU2003237084C1 (en) Estrogen receptor modulators
AU2002232381A1 (en) Estrogen receptor modulators
RU2680716C2 (ru) γ-ДИКЕТОНЫ В КАЧЕСТВЕ АКТИВАТОРОВ WNT/β-КАТЕНИНОВОГО СИГНАЛЬНОГО ПУТИ
JP3182213B2 (ja) ピリミジンの新誘導体、それらの製造法、得られる中間体、それらの薬剤としての使用及びそれらを含有する製薬組成物
CZ302136B6 (cs) Krystalické soli 7-{4-(4-fluorfenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}-(3R,5S)-3,5-dihydroxyhept-6-enové kyseliny
JP2002530411A (ja) 骨疾患の治療または予防のためのプロスタグランジン結合体
CZ286236B6 (cs) Pentacyklické sloučeniny, jejich meziprodukty, způsob jejich výroby a kompozice s jejich obsahem
US6750213B2 (en) Estrogen receptor modulators
JP3165889B2 (ja) 含硫黄複素環化合物、その製造法および用途
WO2004073612A2 (en) Estrogen receptor modulators
CA2424726A1 (en) Estrogen receptor modulators
KR20150130326A (ko) Ep4-매개 질환 및 병태의 치료에서 사용하기 위한 ep4 수용체 선택적 효현제로서 락탐 화합물
JP2013508385A (ja) 治療上有用な、受容体修飾薬としてのクマリン化合物
WO2003087073A1 (en) Estrogen receptor modulators
WO2004091488A2 (en) Estrogen receptor modulators
JP2003505367A (ja) マトリックスメタロプロテイナーゼ阻害剤としての3−アリールスルホニル−2−(置換メチル)プロパン酸誘導体
MXPA01008911A (es) Benzoil-indoles n-sustituidos utiles como agentes estrogenicos..
DE69828522T2 (de) Antithrombotische mittel
US20040044226A1 (en) Estrogen receptor modulators
PL184060B1 (pl) Podstawione związki fenylowe do zastosowania jako środki antagonistyczne endoteliny
JPH04316557A (ja) 6−アリール環状アントラニル酸誘導体
JP2006504697A (ja) 骨同化作用を有する置換ケトホスホネート化合物
EP0430800B1 (fr) Nouvelles benzothiazolinones substituées, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
JPH11310568A (ja) ペンタン酸アミド類